A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Crisaborole (Eucrisa)

Phosphodiesterase 4 Inhibitor class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2017-01-30
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$13.7M in CY2024 Part D spend16K claims · 8K beneficiaries · 329 plans surveyed

Lowest NADAC
$10.68/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$11.67
Across all dosage forms in distribution.
Highest NADAC
$12.65
Range is tight.
Plans with PA
227 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Crisaborole used for?

Crisaborole is a Phosphodiesterase 4 Inhibitor medication tracked in Medicare Part D.

Is there a generic for Crisaborole?

No. Crisaborole is brand-only with no generic equivalents currently in market.

How much does my plan pay for Crisaborole?

Across 329 Part D plans, Crisaborole averages $11.67/unit (NADAC). Lowest available: $10.68/unit. Highest in distribution: $12.65/unit.

Is Crisaborole on the FDA shortage list?

No. Crisaborole is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Phosphodiesterase 4 Inhibitor2 alternatives in D1
01
Apremilast
Brand: Otezla
$89.95Lowest NADAC
5Generic mfrs
$1.68BCY24 Part D spend
Compare →
02
Roflumilast
Brand: Daliresp
$0.312Lowest NADAC
9Generic mfrs
$101.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.